Generation Bio Co

GBIO

Company Profile

  • Business description

    Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

  • Contact

    301 Binney Street
    CambridgeMA02142
    USA

    T: +1 617 655-7500

    https://www.generationbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    115

Stocks News & Analysis

stocks

Apple earnings: Strong performance overpowers headwinds, and we raise our FVE

Our view of Apple shares.
stocks

Coles is winning the supermarket wars but is Woollies the better long-term opportunity?

Our view after first quarter sales updates.
stocks

Microsoft earnings: Strong, including Azure, but overall guidance is in line

We think Microsoft stock is moderately undervalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,182.5024.000.26%
CAC 408,144.7723.700.29%
DAX 4024,222.40264.101.10%
Dow JONES (US)47,562.8740.750.09%
FTSE 1009,732.6615.410.16%
HKSE26,158.36251.710.97%
NASDAQ23,724.96143.810.61%
Nikkei 22552,411.341,085.732.12%
NZX 50 Index13,556.307.980.06%
S&P 5006,840.2017.860.26%
S&P/ASX 2008,894.8036.200.41%
SSE Composite Index3,976.5221.730.55%

Market Movers